AstraZeneca (AZN) Reports Q3 Core EPS of $1.08, Revenues of $9.87B

AstraZeneca (NASDAQ: AZN) reported Q3 Core EPS of $1.08. Revenue for the quarter came in at $9.87 billion versus the consensus estimate of $9.87 billion.

GUIDANCE:

AstraZeneca sees FY2021 Core EPS of $5.05-$5.40, versus the consensus of $3.27.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
• FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
• BMO Capital on FedEx (FDX): 'Guidance Appears Consistent With Our Forecasts'